



## MIO-live 2024 (Mediterranean Interventional Oncology)

### **Practical approach to IO**

Catholic University – A. Gemelli Hospital

Aula Brasca - Rome (IT) 05-06 February 2024

**Course Directors: *Evis Sala, Luigi Natale, Roberto Iezzi***

#### **The MIOLive Scientific Committee**

*Okan Akhan*

*Josè Ignacio Bilbao*

*Antonio Gasbarrini*

*Felice Giuliani*

*Nahum Goldberg*

*Roberto Iezzi*

*Fernando Gómez Munoz*

*Vincenzo Valentini*

***MIOLive 2024 – Liver Edition***

## ***05 February – Monday***

08:30 Registration

08:45 Opening Remarks and Welcome Address

09:05 **OPENING LECTURE:** “The role of Interventional Radiologist in Value-Based Healthcare” – Philippe Pereira

### **I SESSION (9:20 – 13:00)**

Grand Jury: Okan Akhan - Dimitrios Filippiadis – Nahum Goldberg

### **09:20 EARLY STAGE HCC**

- ***What’s new in 2024? The 3 published articles of the last year with greatest impact on patient management*** - Laura Crocetti

### ***EXPERT PANEL DISCUSSION: INTERACTIVE MULTIDISCIPLINARY TREATMENT DECISION***

Moderator: Roberto Iezzi

PANELISTS: Okan Akhan, Dimitrios Filippiadis, Vladimir Dimov, Antonio Gasbarrini, Felice Giuliante, Nahum Goldberg, Maurizio Pompili, Fernando Gomez, Laura Crocetti, Mauro Maccauro

DISCUSSANT: Tobias Jakobs

- *Early Stage Cases from MIOLive 2023: Were the experts right? What have we learned?*
- *Early Stage Cases from MIOLive 2019: Trends and changes in treatment indications over the last 5ys?*
- *New cases*

### ***THINK TANK HCC Meeting: Early Stage***

#### ***Senate vs. People of Rome (Debate & Voting):***

- Center Experience/Availability & Impact on Outcome - Irene Bargellini
- Which device for which lesion? - Francesco Rosario Grasso
- Image-guidance softwares: which evidence? - AnnaMaria Ierardi/Pierpaolo Biondetti
- Multiprobe Approach: Advantages / Disadvantages - Andrea Veltri
- Combined Treatment: Advantages / Disadvantages - Tobias Jakobs
- Percutaneous Segmentectomy: Advantages / Disadvantages - Pierleone Lucatelli
- Radiation Segmentectomy: Advantages / Disadvantages - Thomas Helmberger

12:00 **Live case**

12:15 Lipiodol as Intraprocedural Biomarker in intra-arterial procedures – Thomas Vogl

## **12:30 - SESSION: Current perceptions of IO among competitive medical disciplines for the treatment of CRC**

Moderators: Maria Antonietta Gambacorta – Giampaolo Tortora

- *ESSO point of view: which is the role for curative ablative LT? – Stefan Staettner*
- *ESMO point of view: which is the role for palliative intra-arterial LT? – Arnold Dirk*
- *ESTRO point of view: is there a role for combining interventional radiology and interventional radiotherapy? Luca Tagliaferri*
- *ETF point of view: future role of big data and radiomic for selecting the best treatment – Roberto Luigi Cazzato*
- *Immunotherapy and IO: which role – Alban Denys*

13:30 **Live cases**

## **II SESSION (14:00 – 18:30)**

GRAND JURY: Fernando Gomez Munoz - Thomas Helmberger – Philippe Pereira

### **14:00 MIO Live meets CIRSE Session**

Moderators: Philippe Pereira, Luigi Natale

- *Quality assurance in research - Martijn Meijerink*
- *Importance of a standardised clinical patient pathway - Laura Crocetti*
- *Treatment standardisation and its importance for high quality research in IR/IO - Philippe L. Pereira*
- *How accreditation and research increase access to care - Dimitrios Filippiadis*

15:00 **HONORARY LECTURE:** Artificial Intelligence and Interventional Radiology: ready for it? – Fernando Gomez

15:30 **Live cases**

15:45 **HONORARY LECTURE:** The search for biomarkers to predict outcome and direct therapy in IO – Nahum Shraga Goldberg

### **16:00 INTERMEDIATE STAGE HCC**

- *What's new in 2024? The best 3 published articles I have read in the last year with impact on patient management – Sherrie Bhoori*

*EXPERT PANEL DISCUSSION: INTERACTIVE MULTIDISCIPLINARY  
TREATMENT DECISION*

*Moderator: Maurizio Pompili*

**Panelists:** Bora Peyrnicioglu, Katerina Malagari, Tobias Jakobs, Pierleone Lucatelli, Francesca Ponziani, Marco Biolato, Francesco Ardito – Alban Denys, Alessandro Vitale

**Discussant:** *Thomas Helmberger*

- *Intermediate Stage Cases from MIOLive 2023: Were the experts right? What have we learned?*
- *Intermediate Stage Cases from MIOLive 2019: How treatment indications changed?*
- *New cases*

***THINK TANK HCC Meeting: Intermediate Stage***

***Senate vs. People of Rome (Debate & Voting):***

- a. Intermediate Stage Classification – Alessandro Vitale
- b. cTACE/DEB-TACE/Degradable-TACE/TAE: which evidence? – Olivier Pellerin
- c. TACE vs TARE: which evidence? Which is the best patient? - Jens Ricke
- d. Selective / Superselective / Ultraslective: Time for curative TACE? – Franco Orsi

**18:15 HONORARY CLOSING LECTURE:** "Radioembolization: where we are going" – Riad Salem

**18:30 Live cases**

**19:00** *Plenary Discussion on patients treated*

---

## ***06 February – Tuesday***

### **III SESSION (9:00 – 13:00)**

GRAND JURY: Francesco De Cobelli, Adam Hatzidakis, Afshin Gangi

09:00 **Live cases**

09:30 **HONORARY LECTURE:** Cutting-edge imaging - Afshin Gangi

09:45 **SESSION: IO of the liver beyond HCC and CRC**

Moderators: Adam Hatzidakis, Peter Reimer

- Breast: Thomas Vogl
- Neuroendocrine: Cristina Mosconi
- CholangioCarcinoma: Peter Reimer

10:30 **Live cases**

10:45 **TIPS & New indications**

- Early TIPS & LT – Daniele Morosetti
- TIPS & gastric varices embolization – Emanuela Giampalma

11:30 **ADVANCED STAGE HCC**

- ***What's new in 2024? The best 3 published articles I have read in the last year with impact on patient management - Bruno Sangro***

***EXPERT PANEL DISCUSSION: INTERACTIVE MULTIDISCIPLINARY TREATMENT DECISION***

***Moderator: - Roberto Iezzi***

***Panelist: Jens Ricke, Roberto Cianni, Francesco De Cobelli, Maurizio Pompili, Bruno Sangro, Gabriele Spoletini, Carlo Spreafico, Massimo Venturini***

***Discussant: Irene Bargellini***

- *Advanced Stage Cases from MIOLive 2023: Were the experts right? What have we learned?*
- *Advanced Stage Cases from MIOLive 2019: How treatment indications changed?*
- *New cases*

## ***THINK TANK HCC Meeting: Advanced Stage***

### ***Senate vs. People of Rome (Debate & Voting):***

- Advanced Stage Classification – Irene Bargellini
- Chemoembolization in advanced stage: which TACE? Which evidence? - Federico Colletini
- TARE & advanced stage: which evidence? - Francesco De Cobelli
- ⊖ Immunotherapy & LT in advanced stage: which evidence? - Bora Peyrnicioğlu

### **13:00 Live cases**

---

13:15 Industry Symposium (non CME/ECM)

---

## **IV SESSION (14:00 – 18:30)**

GRAND JURY: Aleksandar Gjoreski – Attila Kovacs – Gianpaolo Carrafiello

### **14:00 SESSION: New Trial & Studies**

Moderators: Aleksandar Gjoreski – Attila Kovacs

- BIOPEARL-One – Geert Maleux
- EMERALD – Cristina Mosconi
- DRAGON TRIALS – Remon Korenblik
- HOPE4LIVER – Luigi Solbiati

15:00 **LECTURE** The Gut Microbiome & HCC: which impact for treatment? – Francesca Ponziani

### **15:15 Live cases**

15:45 **LECTURE** TChemoembolization and CLRM: where we are going – Aleksandar Gjoreski

**16:00 SIO meets MIOLive SESSION**

- Portal Vein Embolization: Is There An Ideal Embolic Agent?" - David C. Madoff
- Do Not Climb the ALPPS: Fast-Track Two-stage Hepatectomy with PVE - Bruno C. Odisio

**16:30 THINK TANK HCC MEETING: Closing Remarks (Roberto Iezzi)**

**17:00 HONORARY LECTURE:** Transradial Approach and IO: Future Perspectives  
- Marcelo Guimaraes

**17:20 Live Cases**

17:45 Plenary Discussion on patients treated

**18.00 End**